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Stem cellThe most commonly used technique for the treatment of stress urinary incontinence (SUI) in women is the
suburethral polypropylene sling, using either a retropubic or transobturator tape approach This treatment results
in a cure rate of over 80%, based on both subjective and objective evaluations. Biological slings have been largely
abandoned due to lack of efficacy. Despite the high success rates, 10–20% of women remain incontinent.
Cell-based therapymight offer solutions for the future both for the primary setting as for the treatment of failures.
Preclinical studies suggest that stem cells (SC) can enhance the recovery of damaged tissue either by direct inte-
gration and replacement of damaged tissue (differentiation) or by secreting factors that influence host response
mechanisms (paracrine effect).
The clinical data to date do not allow strong efficacy conclusions, except that SC therapy seems to be safe in the
short term.Most published studies use autologous cells. Allogeneic cell sources need to be investigated aswell to
allow ready-to-use solutions in the future.
Most importantly, we need better insight into themechanisms of action.We needmore basic stem cell research,
better acute and chronic animal models, better investigational tools and more efforts using tissue engineering
approach.
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The lifetime risk of pelvic floor surgery among women at 80 years
old was 11.1% where 29% had at least one previous surgery [1]. More
than 15 years later, the lifetime risk remained the same about 12.2%,
where 6.2% women had at least one previous surgery of whom 19%
had repeat operations. These results did not necessarily imply the reop-
eration rate for slings in incontinence patients. In the latter study,
midurethral slings and periurethral injectables as initial urinary inconti-
nence (UI) surgery have been considered as independent predictors for
reoperation.Midurethral slings as initial surgery inUI patientswere 70%
less likely (HR= 0.3; 95% CI= 0.15–0.6; p=0.001) to experienced re-
operation, meanwhile periurethral injectables were 9-fold (HR= 9.05;
95% CI = 2.42–33.8; p=0.001)more frequent to experienced reopera-
tion following treatment. The reoperation rate for slings in incontinence
patients was 3.2% in the Abdel-Fattah cohort, while it was 5% in our co-
hort. While surgeon in high-volume centers might play an important
role in the significant decline of failure of pelvic floor surgeries, we be-
lieve that better meshmaterials and surgical techniques nowadays con-
tributed as well.
Sling surgery has become the surgical therapy of choice for stress in-
continence inwomen. Slings can be classified according to their compo-
sition: autologous, heterologous, synthetic or to the surgical approach:
pubovaginal or retropubic, transobturator (inside-out or outside-in) or
single-incision mini-sling. Autologous sling is routinely used still in
type 3 incontinence. Worldwide the number of Burch colposuspension
is declining in favor of midurethral slings [2,3]. All of the sling surgery
approaches have advantages and risks; therefore, it is important that
the surgeon is aware of these aspects in order to counsel patients in
an honest and reliable way. Despite the high success rate, synthetic
sling surgeries are not without complications. Recurrence, urinary re-
tention lasting more than 6 weeks, erosions, extrusions, groin pain, leg
pain, bladder perforation, urethral perforation, vaginal perforation and
deep vein thrombosis are complications that might occur [4]. Re-
searchers have been focusing to investigate other treatment options
than surgery that might address these issues, where cell-based therapy
might play a role. Cell therapy might be a potential option to solve the
underlying problem of SUI patients rather a symptom-relief approach.
2. Indications for sling surgery
SUI with urethral hypermobility is the standard indication for any
sling. More complex conditions such as mixed incontinence (stress
and urgency incontinence) might respond to sling surgery as well, but
usually subsequent treatment for the urgency componentwill be neces-
sary. Also recurrent incontinence after previous failed slings can be
treated by secondary synthetic or autologous slings. For patients with
intrinsic sphincter deficiency and severe incontinence, autologous
sling can be positioned as a “tight” sling that compress the urethra. In
these cases, intermittent catheterization will be necessary to ensure
bladder emptying.
3. Autologous pubovaginal sling
The use of autologousmaterial to support the bladder neck and ure-
thra goes back more than 100 years [5]. When Burch colposuspension
becamemore popular, the use of fascial slingswas restricted to complex
or failed cases. Burch suspension is a type of bladder neck suspension
for stress urinary incontinence where the lateral vaginal fornices is
fixed to the iliopectineal ligaments. From 1998, when the tension-free
transvaginal tape (TVT) became widely available, fascial slings became
nearly obsolete. In recent years, however, there is a renewed interest.
Complications of synthetic slings such as erosion, perforation or ob-
struction often result in the partial or complete removal of the synthetic
sling, leading to recurrent stress incontinence. In these cases, thePlease cite this article as: L. Hakim, et al., Slings for urinary incontinence a
http://dx.doi.org/10.1016/j.addr.2014.11.006traditional fascial slings seem to be used again to avoid the use of syn-
thetic material [6].
The most common indications for an autologous pubovaginal sling
are intrinsic sphincter deficiency with or without urethral hypermobil-
ity and a prior failed incontinence procedure. Also, certain patients with
severe SUI due to urethral hypermobility may be better served with an
autologous pubovaginal sling procedure because of the long-term suc-
cess and durability of this sling. However, Jones et al. (2010) described
that inform-consent pre-operatively should be made to patients that
transvaginal tape (TVT) placement carries a risk potentially exceeding
4% of tape-related complications requiring further surgical intervention
[7]. Options of treatment should me made thoroughly to patients to
freely decide, regarding the potential complication that may occur.
4. Retropubic tension-free vaginal tape
Some developments have paved the way to the introduction of the
revolutionary retropubic tension-free vaginal tape TVT in 1996. First, it
was recognized that the functional restoration of the urethral closing
mechanism was more important than the correction of the anatomy.
The second development was the acknowledgement of the importance
of the midurethra in the continence mechanism. This was supported by
the discovery of the pubourethral ligaments, the observation that the
maximum urethral closing pressure is located midurethrally and that,
in continent women, the urethra closes in the middle part. Therefore,
the new concept of the integral theory by Petros and Ulmsten stated
that SUI was caused by a lacking midurethral closing mechanism. This
could be caused by failure of the pubourethral ligaments, lacking sup-
port of the anterior vaginal wall to the midurethra or by defective func-
tioning of the pubococcygeal muscles that support the adjacent part of
the urethra. Connective tissue structures (ligaments) are regarded
very important in the integral theory and therefore surgical treatments
are aiming at restoring these ligaments.
5. Transobturator tapes
A new era of stress incontinence surgery started with the introduc-
tion of the TVT. This new classic gives support to the midurethra and
prevents dislocation of themidurethra during intra-abdominal pressure
rise. The midurethral tape is U-shaped and runs retropubically. The
most frequently occurring complication is bladder perforation when
the needles with the connected tapes pass behind the pubic bone.
Since the bladder is in the vicinity, it is easily perforated. Therefore,
urethrocystoscopy is recommended during the procedure. In order to
avoid bladder perforation and urethrocystoscopy during the procedure,
the transobturator approach was introduced by Delorme [8,9]. The
transobturator tape (TOT) runs from one obturator foramen along the
anterior vaginal wall via the midurethra to the opposite obturator fora-
men in a V-shaped fashion
6. Single-incision slings
Minimizing the size of the sling and reducing the number of inci-
sions lead to the appearance of the so-called mini-slings. These single-
incision slings are fixedwith harpoon-like devices in the obturatormus-
cle. Several types of these slings have been introduced and many of
those lack good scientific data to support their use in the routine prac-
tice. The first mini-sling was the TVT-Secure. After initial enthusiasm,
it rapidly became clear that the results were about 10% less than with
standard transobturator or retropubic approaches. The TVT-Secure
was withdrawn from the market in 2012, but the poor results continue
to confound the systematic reviews and meta-analyses on mini-slings
to date. A recent systematic review excluding the TVT-Secur data by
Mostafa et al. [10] found no significant differences between data pub-
lished on mini-slings and standard midurethral slings. The mini-slings
showed an earlier recovery. These data should be interpreted withnd the application of cell-based therapy, Adv. Drug Deliv. Rev. (2014),
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data only reflect midterm follow-up.
7. Which sling to choose?
Recently, a systematic review and meta-analysis was performed
concerning sling surgery for SUI in women [11]. Based on the findings
of randomized controlled trials, several conclusions could be drawn:
a. Midurethral slings versus Burch: No difference between objective
cure, either intervention can be proposed but the decision should
take into account potential adverse events and concomitant surger-
ies. Burch suspension is more invasive since laparotomy needs to be
conducted to perform the fixation between the lateral vaginal forni-
ces and the iliopectineal ligaments, therefore this approach should
be considered only when concomitant surgery is necessary.
b. Autologous pubovaginal sling versus Burch: Subjective and objective
cure are better in autologous pubovaginal slings.
c. Autologous pubovaginal sling versus midurethral sling: Subjective
cure favors midurethral sling.
d. Obturator sling versus a retropubic sling: Adverse event analysis
showed that urgency symptoms after surgerywere common follow-
ing a retropubic sling. Hence, both retropubic and obturator slings
can be recommended but the decision should be balanced for ad-
verse events, where TVT showed more evidence.
e. Mini-slings versus midurethral slings: Objective and subjective cure
rate significantly favors midurethral slings.
The EuropeanAssociation of Urology guidelines, however, are slight-
ly different, maybe due to the PICOmethodology that was used in creat-
ing the guidelines [12]:
a. Midurethral slings should be offered to women with uncomplicated
SUI as the initial surgical intervention
b. Colposuspension (open or laparoscopic) or autologous fascial sling
should be offered to women with SUI if midurethral sling cannot be
considered. Colposuspension is a surgery that involves the placement
of permanent stitches at the level of the bladder neck, to lift up the
bladder and correct the problem of stress urinary incontinence. This
can be perform whether by open surgery or using minimal-invasive
approach (laparoscopy). Meanwhile, in the autologous pubovaginal
sling procedure, a support constructed of rectoabdominal fascia to
stabilize the bladder neck from underneath is performed in order to
treat SUI.
c. Womenwho are being offered a retropubic synthetic sling should be
warned about the relatively higher risk of perioperative complica-
tions compared with transobturator insertion.
d. Women undergoing autologous fascial sling should be warned that
there is a high risk of voiding difficulty and the need to perform
clean intermittent self-catheterization; ensure they are willing and
able to do so.
e. Women being offered a single-incision sling device, for which an ev-
idence base exists, should be warned that they may be less effective
than standard midurethral slings and that efficacy beyond 1 year re-
mains uncertain. Single-incision sling devices without level 1 evi-
dence of effectiveness should only be implanted as part of a
structured research program.
8. Biological slings
Biological xenografts were introduced in the late nineties. Theoreti-
cally, they would yield less complications such as erosion or extrusions
and the incorporation in the native tissue would be better. Pelvicol™
(cross-linked porcine dermis) and Intexen™ (non-cross-linked porcine
dermis) were used in the treatment of SUI and of pelvic organ prolapse
with variable results. The long-term success to treat SUI seemed to bePlease cite this article as: L. Hakim, et al., Slings for urinary incontinence a
http://dx.doi.org/10.1016/j.addr.2014.11.006inferior to standard synthetic slings. A recent RCT comparing Pelvicol
slings with autologous pubovaginal sling and synthetic midurethral
slings showed that after 1 year, the continence rate was only 63% for
Pelvicol slings, while it was 90% for both autologous pubovaginal slings
and midurethral synthetic slings [13]. It was also shown that these bio-
materials did not integrate very well into the host tissue and lost tensile
strength over time [14,15].
Small intestinal submucosa is another biomaterial that consists of
decellularized porcine submucosa. Since a single layer of submucosa is
difficult to handle and does not provide enough strength, multiple
layers are used: 4- and 8-layer constructs are available. Again, after ini-
tial enthusiasm, the continence results proved to be disappointing [16,
17]. Moreover, in several case reports, inflammatory reactions to this
material have been described [17,18].
In general, the use of biological slings has faded in the recent years
because of the aforementioned results, the doubts about long-term effi-
cacy and the fear of transmittable diseases. The ease of use of the current
synthetic slings, the goodmidterm and long-term results of these slings
and the limited number of serious complications have made the use of
biomaterial slings virtually obsolete.
9. Will cell-based therapy or tissue engineering provide benefit for
the treatment of SUI?
Given the success of the synthetic slings one couldwonder if there is
anything to improve. The success rate of 85–90% implies that 15–10% of
patients will have persisting incontinence despite having undergone
sling surgery. Other patients will have had partial or complete sling re-
movals for obstruction or for erosion and will need subsequent treat-
ment for incontinence. A proportion of patients will also develop de
novo urgency following sling surgery, which is not frequent but may in-
validate pain. Hence, despite the fact that in the majority of patients
sling surgery will lead to significant improvement or cure of the conti-
nence, major challenges for future research and product development
lie ahead.
The development of the biological slings unfortunately did not really
work. Two lines of research are now being followed. On the one hand,
researchers try to design scaffolds that are seeded with cells and that
can be used as tissue-engineered meshes that integrate in the host tis-
sue. On the other hand, sphincter regeneration is being attempted by
injecting a variety of stem cells into the sphincter zone, hoping that
this will restore the function of the weakened sphincter muscle and
support tissues (Fig. 1). Results of clinical trials using autologous tissue
are awaited.
10. Regenerative medicine for the treatment of SUI
Up to date, the application of regenerativemedicine for SUI has been
dominantly focusing on cell therapy in order to restore the natural con-
tinence mechanism. The rationale behind this is that both conservative
and surgical treatments for SUI ended with recurrences and/or compli-
cations in some patients in the long-term outcome, such as erosion, re-
tention, retreatment false route, etc. These treatments are thought to
focus more on relieving symptoms rather than treating the underlying
disease.
Clinical trials for cell therapy in SUI are scarce, mainly due to ethical
or regulatory reasons. If existing, they are limited to non-randomized
studies with small sample size or even case reports. On the other
hand, preclinical trials kept going on, showing a better understanding
in themechanism of action on how externally injected cellsmay restore
the urethral function.
The role of tissue engineering for SUI has been increasingly studied
in order to enhance cell therapy. Many preclinical studies exist and
showed the benefit of combining additional substances to cell therapy
for SUI treatment. Unfortunately, this approach has not been brought
into the clinical setting.nd the application of cell-based therapy, Adv. Drug Deliv. Rev. (2014),
Fig. 1. A graphical abstract of different approaches for the treatment of stress urinary incontinence. In the clinical setting, surgical efforts have been introduced to restore the urethral sup-
port in SUI patients using different approach andmeshmaterials: synthetic slings, autologous slings, xenograft slings, Burch colposuspension and autologouspubovaginal slings. The role of
cell therapyhas been introduced in thepreclinical settings in order to restore both skeletal and smoothmuscles of the external urethral sphincter, using both autologous and allogenic stem
cells. Paracrine factors has been shown to be responsible for the migration of stem cells to the site of injury, while lack of evidence showed the integration of these cells into the muscles.
The use of stem cells for tissue engineering has also been introduced to restore the urethral support.
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The advantage of injecting muscle-derived stem cells (MDC) over
the injection of fibroblast in the damaged sphincter was shown by
Kwon et al. [19]: both MDC and fibroblast injection increased the LPP
in an SUI rat model but only MDC significantly improved urethral mus-
cle strip contractility.Moreover, urinary retention developedwith high-
dose fibroblast injection, but not with MDC injection.
In the preclinical setting, multipotentmesenchymal stem cells (MSC)
present in adults in most of the tissues derived from mesoderm have
beenmostly used for SUI. Different types of stem cells have been applied:
skeletal muscle derived (myoblasts, satellite cells, muscle progenitor
cells and muscle-derived stem cells), bone marrow stem cells (BMSC),
human umbilical mononuclear cells, adipose-derived stem cells (ADSC)
and modified/sorted stem cells which show various efficacy [20]. These
cells have been proven to demonstrate nerve regeneration and improve
musculature profiles of the external urethral sphincter, which lead to
functional improvement. Paracrine factors have been thought to be re-
sponsible for the improvement rather than cellular differentiation [21].
Lin et al. (2010) observed possible differentiation of ADSC into smooth
muscle of a vaginal dilatation (VD) model following intravenous ADSC
injection by the appearance of Edu (5-ethynyl-2′-deoxyuridine)-positive
nuclei localized within cells that stained positive for alpha-smooth mus-
cle actin (α-SMA) [22]. Mesenchymal stem cells and CD34+ have been
proven to differentiate into muscular and vascular components. On the
other hand, the use of cytokines and growth factors such as hipoxia-
induced factor-1, vasculo-endothelial growth factor, basic fibroblast
growth factor and insulin-like growth factor have shown to enhance
the viability and direction of stem cell differentiation [23]. More recently,
Dissaranan et al. showed that mesenchymal stem cells migrate to the
urethra and vagina and facilitate recovery of continence most likely via
secretion of paracrine factors. The authors also showed that intravenous-
ly injected MSCs preferentially engraft in the smooth muscle of urethra
and vagina based on histological analysis and confocal imaging. Both
MSCs and the conditioned culture medium the authors use showed
promising results [24,25].Please cite this article as: L. Hakim, et al., Slings for urinary incontinence a
http://dx.doi.org/10.1016/j.addr.2014.11.006Among these type of cells, ADSC have the advantage of being abun-
dantly available and of being easy to prepare. This leads to a shorter
preparation time prior to its use and thus makes them more suitable
for clinical application. Unlike bone marrow-derived cells, ADSC would
less likely cause morbidity when harvested from humans. Although
novel sources of stem cells have been introduced for urologic applica-
tions such as placental and amniotic fluid stem cells, urine-derived
stem cells and umbilical cord-derived stem cells, none of these have
been applied for SUI treatment [26].
In terms of efficacy, the use of stem/progenitor cells treatment for
SUI has reached a major step nowadays, by the fact that it has been
brought it into the clinical setting. Some clinical trials have shown
promising results for the treatment of SUI [27–29].
Unfortunately, some drawbacks exists in preclinical trials at this
moment.
First, vaginal distension and pudendal nerve injury models in ro-
dents that have been commonly used to simulate SUI in women are
acute models in nature, while SUI in women is a chronic symptom
[30–37]. The question rises whether stem cell applications in these
models should or could be used as curative-intent treatments or if
they should be considered as preventive treatments (e.g., injecting
cells after vaginal delivery to prevent future SUI).
The choice of an adequate preclinical model is difficult. Next to rat
models, canine models have been described [38]. Other models such
as nonhuman primates might be more relevant to the human situation,
but the use of these models is obviously limited. Despite these limita-
tions, Badra et al. [39] showed nicely thatmuscle-derived stem cell inte-
grated well in the sphincter system after pudendal nerve injury in
cynomolgus monkeys and that this also resulted in a better sphincter
function.
Second, current models are in general not durable and tend to
recover spontaneously in a short period, unlike SUI in women. Ef-
forts were made to develop a more durable model by the combina-
tion of methods of injury, longer time of injury and/or using
additional substances to prolong the natural recovery of these
models [40–45].nd the application of cell-based therapy, Adv. Drug Deliv. Rev. (2014),
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ment in musculature of the EUS following stem cells injection based
on histological examination. These histological images, however,
might just show transplanted stemcells and are not a proof of functional
integration. Unfortunately, not many of these studies could identify the
differentiation of stem cells [20].
Fourth, the best deliverymethod of stem cells still needs to be inves-
tigated. While transurethral injection of stem cells was employed al-
most exclusively in clinical trials, periurethral injection was used in all
preclinical trials. Intravenous injection was also used in one preclinical
study [20]. Du et al. showed that BMSC,muscle-like cells and calciumal-
ginate composite gel have the potential to differentiate intomuscle cells
in themicroenvironment of an SUI ratmodel. However, longer observa-
tion time is still needed to further inducemyoblast proliferation to form
a more complete muscle cell structure and gradually replace the gel to
provide sufficient support for the urethra. In addition, the control of al-
ginate gel porosity, the best combination ratio of the gel with stem cells
or muscle-like cells, the best time, cytokines, growth factors and other
factors, may affect cell proliferation and the formation of muscle fiber
by tissue engineering and these issues need to be studied further [46].
10.2. Limitations in the method of assessment of SUI models
Different methods to determine SUI in lab animals have been used,
most commonly leak point pressure (LPP) and electromyography of
the external urethral sphincter (EUS EMG) [47–49]. Thesemethods pro-
vide limitations since LPP requires a learning curve before stable results
can be achieved. Also, LPP measurements are possible inconsistent re-
garding the bladder volume since its emptiness was not confirmed
prior to measurements.
EUS EMG is invasive and traumatic due to concentric needle place-
ment and potentially induces a bias due to noise of the rawEMG signals.
Recently, high-frequency microultrasound (μ US) has been intro-
duced as a reproducible method to assess urethral function in female
rats following simulated birth injury [50]. The authors showed that
μUS could be used to assess EUS bursting during the 2nd-phase of mic-
turition cycle using predetermined parameters: interburting interval
(IBI) and length of bursting (LOB). Uninjured rats showed a rhytmic pat-
tern of EUS bursting, while none of the VD rats showed EUS bursting
during urine leakage.
Furthermore, in a subsequent study, the same group validated μUS to
EUS EMG,which has been considered as the gold standard to assess ure-
thral function. Simultaneous measurement of cystometography (CMG),
μUS and EUS EMG in 15 nulliparous-uninjured rats at different saline-
infusion rates of 5, 10 and 60ml/h was performed. No significant differ-
ences of IBI and LOBwere foundwhen μUS and EUS EMGwas compared
within group of different infusion rates (Fig. 2). Meanwhile, μUS or EUS
EMG showed no significant differences of IBI and LOB when measured
at different infusion rates (Fig. 3). However, all parameters of CMG
(baseline pressure, BP; threshold pressure, TP; peak pressure, PP) tend
to increase as the infusion rate increases. The rate of bursting (ROB) re-
mains stable while the total length of each bursting (TLB) became lon-
ger as the infusion rates increases, indicating that rats void at a longer
time but with consistent rate of bursting (Fig. 3). In summary, the au-
thors concluded that both EUS EMG and μUS could be used to assess
urethral function with consistent results at different infusion rates.
μUS is advantageous to EUS EMG and LPP as being less-operator depen-
dent, non-invasive, no bias possibilities due to raw signals and fewer an-
imals needed for experiments. (See Fig. 4.)
Therefore, at this point, the preclinical study of stem cells for SUI re-
mains important and further studies need to be conducted emphasizing
on developing a durable model of SUI, a reproducible method to deter-
mine SUI, the mechanism of stem cells action, the differentiation of ap-
plied cells, the optimum dosage, the most efficacious type of cells and
the route of injection. In any event, stem cell transplantation appears
to be a promising treatment for SUI [45].Please cite this article as: L. Hakim, et al., Slings for urinary incontinence a
http://dx.doi.org/10.1016/j.addr.2014.11.00610.3. Cell therapy for SUI: at the bedside
Unlike the application for non-urological diseases such as cardiology,
randomized double-blind clinical trials for SUI in humans are scarce and
involve small sample sizes. Moreover, most of the available studies did
not provide empirical data, not allowing to draw any sound conclusion
[51]. Two of them were even retracted due to ethical and undisclosed
reasons.
Also different methods have been used to transplant the cells of in-
terest in these studies. Transurethral or periurethral delivery under ul-
trasound or cystoscopy guidance have been used but the optimal
technique remains to be elucidated.
Cell therapy for SUI has been initiated by Chancellor et al. (2000) in a
preclinical trial which studied the role of intraurethral injection ofmyo-
blasts to enhance the urethral wall coaptation and to possibly improve
the urinary sphincter function [52]. This methodology is now being in-
vestigated in a American/European multicenter study.
Mitterberger et al. (2007) had so far provide the largest-sample size
(n=123) of cell therapy in women with a follow-up of 1 year. The au-
thors observed a complete improvement in 79% of women 36–84 years
of age, 13% of substantial improvement and 8% of slight improvement
following autologous injection of fibroblast and myoblast derived from
skeletal muscle [53]. This group, however, had to withdraw their publi-
cations because of ethical issues. The composite continence score they
developed to show this success rate is no longer used and the highly fa-
vorable results cannot be trusted.
Some other studies showed cure rate between 40% and 75% [54–56].
Sèbe et al. [54] injected 12 women with persistent SUI after failed
surgery with muscle-derived stem cells. While the quality of life im-
proved in 50% at 3 months time, 3 patients became dry, 7 improved
and 2 worsened.
Carr et al. [55] injected 8womenwith SUI ofwhom3withdrew from
the trial early. Of the 5 remaining patients, one achieved continence
while the others showed some improvement. Importantly, they noted
that the onset of improvement was only after 3–8 months.
The same author also published a dose finding study [56]. A total of
38 women underwent intrasphincteric injection of low doses (1, 2, 4, 8
or 16 × 106) or high doses (32, 64 or 128 × 106) of autologous muscle-
derived cells (AMDC). Intrasphincteric injection of AMDC in these doses
seemed to be safe. Additionally, efficacy data suggested a trend toward
greater efficacy with doses of 32 × 106 AMDC or greater.
Lee et al .[56] used umbilical cord stem cells in 39 women with SUI.
He showed subjective improvement in 72% at 1 year. They also noted a
progressive improvement over time since more patients were cured at
12 months than at 3 or 6 months. However, this study has major meth-
odological flaws and should be interpreted with caution.
Blaganje et al. [57] injected autologous muscle-derived stem cells in
38 women with SUI. Initially the women were treated with electrical
stimulation alone for 6 weeks. Then the stem cells were injected, and
another 6 weeks of electrical stimulation were given. At the end of
this 6-week period, 5 women were cured and 29 improved. Unfortu-
nately, there was no control group.
Kuismanen et al. [58] injected 5 women with ADSC of whom 1 be-
came continent after 6 months and 2 more at 12 months, using the
cough stress test as outcome measure.
So far, no randomized controlled data are available, nor are there any
long-term data. Next to the lack of good data, a health-economic analy-
siswill be needed to establish the potential role of this therapy in the fu-
ture. Dosage of cells injected, number of injection and the method of
delivery are other factors that need to be addressed in a future study.
However, at this moment, the clinical trials that have been conduct-
ed in humans have at least provided evidence that stem cells for SUI are
safe in the short term and that the effect of the injected cells only be-
comes apparent after a fewmonths. Efficacy needs to be elucidated fur-
ther since some number of studies showed clinical improvement but
some others not [51].nd the application of cell-based therapy, Adv. Drug Deliv. Rev. (2014),
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The role of tissue engineering for the treatment of SUI started with
the idea that addition of cytokines and/or growth factors may enhance5 ml/hr 10 ml/hr 60 ml/hr
0
10
20
30
40
B a s e lin e P r e s s u r e
Infusion Rate
Pr
es
su
re
 (c
m
H
2O
)
O ne -w a y A N O V A p< 0 .0 0 01
5 ml/hr 10 
0
10
20
30
40
50
T h r e s h o l
Infusio
Pr
es
su
re
 (c
m
H
2O
)
O ne -w a y A
0
2
4
6
8
R a te o f B u rs tin g
Infusion Rate
Fr
eq
ue
nc
y 
(s
ec
)
O ne -w a y A N O V A p= 0 .5 5
A
B
5 ml/hr 10 ml/hr 60 ml/hr
Fig. 3.A bar chart of voiding analysis. (A) Voiding analysis showed baseline pressure (left, BP), th
10 and 60 ml/h. These parameters tend to increased significantly as the infusion rate increases
fusion rates were applied (p= 0.55); meanwhile, the TLB tend to be higher as the infusion rat
Please cite this article as: L. Hakim, et al., Slings for urinary incontinence a
http://dx.doi.org/10.1016/j.addr.2014.11.006the viability and direction of stem cells differentiation. Practically, the
application of tissue engineering can be classified as the use of cell-
growth supporting substances and/or materials (bio-compounds) to
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folds may release growth factors upon degradation in a controlled and
predictable manner, thus enhancing recovery or stem cell differentia-
tion. The use of mesh in scaffolds can be in general divided into non-
absorbable mesh and absorbable mesh types. The latter was meant to
be absorbed with an adequate tensile strength until the cells grow
and pick up a blood supply, thus mimicking the use of autologous
fascia.
Zou et al. [59] compared an acellular silk sling with a sling seeded
with BMSCs and observed a better integration in the cell seeded group
between the silk sling and the native urethral structure at 12 weeks fol-
lowing injury of the sciatic nerve. The BMSCs-seeded silk sling group in
this study showed a double-increase of collagen fiber formation with a
higher Young's modulus as compared to non-seeded group, suggesting
that the continence mechanism improved.
Meanwhile, Zhao et al. [60] seeded ADSCs onto poly-lactic-co-glycolic
acid (PLGA; synthetic scaffold) microparticles containing nerve growth
factor (NGF) and injected them periurethrally following bilateral puden-
dal nerve transsection in female rats. The authors showed improvement
of continencemechanismby an increase of LPP compared to groupswith-
out PLGA and/or NGF. The study also emphasized the role of NGF to pro-
long the survival of ADSCs. This enhanced the urethral smooth muscle
profile and increased the density of neurofilaments in the sphincter lam-
ina propria, thus increasing the urethral resistance.
Various kinds of scaffolds have been proposed. Poly-1,8-octanediol-
co-citrate (POC) has been studied by Sharmaet al. to promote angiogen-
esis and increase vascular growth [61]. The addition of heparin sulfate
that bound to growth factors prevented the enzymatic degradation,
which in turn improved tissue healing [61]. Although potentially useful,
this scaffold has not been studied for SUI in the preclinical setting.Please cite this article as: L. Hakim, et al., Slings for urinary incontinence a
http://dx.doi.org/10.1016/j.addr.2014.11.006Recently, Shi et al. (2013) developed a tissue-engineered bulking
agent consisting of ADSCs and silk fibroin microspheres (SFM) to treat
SUI and injected them periurethrally in bilateral pudendal nerve-
transected rats. The SFM improved urethral resistance as showed by
the increasing LPP at a short-term period (4 weeks following injury),
but its efficacy disappeared by 8 and 12 weeks. Conversely, when
ADSCs were seeded with SFM, recovery of LPP could still be observed
up to 8 and 12 weeks, thus providing a longer-term efficacy.
Cannon et al. [62] used a small intestine submucosa sling in a rat
model of SUI following bilateral proximal sciative nerve denervation.
One groupwas implantedwith the sling, while the other groupwas im-
planted with a sling seeded with muscle-derived cells. The results
showed no advantage of adding cells.
The production of scaffolds and the attachment of oral fibroblasts
and ADSC to these scaffolds has been studied extensively by Roman
et al. [63,64]. Further studies on the host response to these constructs
are awaited.
In the future, we believe that tissue engineering strategieswill be in-
creasingly applied in order to enhance cell therapy and to improve sling
properties.
11. Conclusion
The gold standard in the treatment of SUI inwomen is the suburethral
macroporous polypropylene sling by a retropubic or transobturator ap-
proach. Most slings result in a cure rate of more than 80% that is main-
tained for a long time, although some evidence showed potential
surgical complications mini-slings are still being evaluated. Their role re-
mains to be elucidated. Biological slings proved to yield inferior results
and have been largely abandoned.nd the application of cell-based therapy, Adv. Drug Deliv. Rev. (2014),
8 L. Hakim et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxxFor patients with persistent incontinence after sling surgery, a sec-
ondary sling might be an acceptable options. Despite the high success
rates, 10–20% of women continue to be incontinent. Also, sling erosion,
obstructive voiding and persistent pain are possible complications of
sling surgery.
Cell-based therapy and tissue engineering for SUI might be a solu-
tion for the future [65].
Preclinical studies suggest that stem cells can differentiate into
smooth muscle cells and that they can enhance the recovery of dam-
aged tissue by integration and replacement of damaged tissue. On the
other hand, a paracrine mechanism of action, by secreting factors that
modulate local responses to the damage, has been shown. Modifying
sling properties using tissue engineering seems promising as well.
The paucity of clinical data and the poor design of the few clinical tri-
als do not allowdrawing any sound conclusions at thismoment.Most of
these studies use autologous cells, meaning that there will be a time
delay between the harvesting of the cells and the re-injection after cell
sorting and expansion. Allogeneic cell sources could avoid this draw-
back and need to be investigated to allow ready-to-use solutions in
the future.
However, most importantly, we need better insight in the mecha-
nism of action of cell-based therapy for SUI. Therefore, we need more
basic stem cell research, a better understanding of the tissue changes
after chronic pelvic floor dysfunction, better acute and chronic, animal
models, better investigational tools and more effort into tissue
engineering.
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